BioSpace News Archive

Wave Life Sciences Ltd., a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, held a virtual analyst and investor R&D Day, which highlighted the company’s growth strategy for building the leading RNA medicines company.

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced that the Company has entered into a partnership with ResMed Germany to increase OSA awareness and therapy penetration in the German market.

PTC Therapeutics, Inc. announced further strategic prioritization and associated workforce reduction.

Medicenna Therapeutics Corp. announced the voting results from the Company’s annual and special meeting of shareholders held September 28, 2023.

Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, announced that Chief Executive Officer Masoud Toloue will speak on a panel at Goldman Sachs Alzheimer’s Disease Day on Tuesday, October 3, 2023.

Envoy Medical® Corporation (“Envoy”), a hearing health company, today announced that the proposed merger with Anzu Special Acquisition Corp I

Biosenta Inc. (“Biosenta” or the “Company”) (CSE: ZRO) is thrilled to announce a pivotal discovery led by Dr. Mehdi Mohammadi Ashani, a Postdoctoral Researcher under the mentorship of Dr. Ian Lewis and Dr. Maen Husein at the University of Calgary.

Orsini Specialty Pharmacy has been selected by Amicus Therapeutics to dispense Pombiliti™ and Opfolda™, a two-component treatment approved for certain patients with late-onset Pompe disease.

Nanostics is thrilled to announce the availability of the ClarityDX Prostate test at its newly accredited clinical lab in Edmonton, Alberta.

BioNxt Solutions Inc. is pleased to announce that, further to its news releases dated August 4 and August 28, 2023, the Company has closed the second tranche of its non-brokered private placement in the amount of 2,500,000 common shares in the capital of the Company at a price of $0.265 per Share for gross proceeds of $662,500.